SCHEMBL15613558

SCHEMBL15613558

Cc1ncc(COc2cc(F)cc(Oc3ccc(-c4nn(C5CCOCC5)c5ncnc(N)c45)cc3)c2)cn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 11/20 0.52
▸ LCK P06239 5/20 0.52
▸ LYN P07948 1/20 0.52
▸ NUDT14 O95848 1/20 0.51
▸ NUDT5 Q9UKK9 1/20 0.51
▸ SRC P12931 8/20 0.49
▸ KDR P35968 3/20 0.49
▸ TEK Q02763 1/20 0.49
▸ EGFR P00533 4/20 0.48
▸ PIK3CD O00329 4/20 0.48
▸ ABL1 P00519 2/20 0.48
▸ HCK P08631 2/20 0.48
▸ PIK3CA P42336 2/20 0.48
▸ PIK3CB P42338 2/20 0.48
▸ MTOR P42345 2/20 0.48
▸ PIK3CG P48736 2/20 0.48
▸ EPHB4 P54760 2/20 0.48
▸ PRKDC P78527 2/20 0.48
▸ PI4KB Q9UBF8 2/20 0.48
▸ ITK Q08881 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15613529 0.93 BTK (0.61) BTKLCKLYNNUDT14NUDT5
SCHEMBL15613585 0.93 BTK (0.51) BTKLCKLYNNUDT14NUDT5
SCHEMBL15613652 0.92 BTK (0.54) BTKLCKLYNNUDT14NUDT5
SCHEMBL18269007 0.91 SRC (0.57) BTKLCKLYNNUDT14NUDT5
SCHEMBL15613512 0.90 BTK (0.61) BTKLCKLYNNUDT14NUDT5
SCHEMBL16886194 0.90 BTK (0.49) BTKLCKLYNNUDT14NUDT5
SCHEMBL18269008 0.89 BTK (0.52) BTKLCKLYNNUDT14NUDT5
SCHEMBL18269173 0.88 BTK (0.53) BTKLCKLYNNUDT14NUDT5
SCHEMBL15613783 0.88 BTK (0.49) BTKLCKLYNNUDT14NUDT5
SCHEMBL19484826 0.88 BTK (0.49) BTKLCKLYNNUDT14NUDT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
WO-2013177668-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2013-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK BTK 10/4885LCK 3/4885LYN 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback